The Functional Biology of Dystrophin: Structural Components and the Pathogenesis of Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy: Advances in Therapeutics

Volumn , Issue , 2006, Pages 21-54

  Ozawa, Eijiro ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 47649100065     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849374456-5     Document Type: Chapter

References (121)

1. Arahata K, Ishiura S, Ishiguro T, et al. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 1988; 333:861-863.
2. Watkins SC, Hoffman EP, Slayter HS, Kunkel LM. Immunoelectron microscopic localization of dystrophin in myofibres. Nature 1988; 333:863-866.
3. Engel A, Ozawa E. Dystrophinopathies. In: Engel A. Franzini-Armstrong C, ed. Myology. New York: McGraw-Hill, 2004:961-1025.
4. De Le Porte S, Morin S, Koenig J. Characteristics of skeletal muscle in mdx mutant mice. Int. Rev Cytol 1999; 191:99-148.
5. Batten FE. The muscle spindle under pathological conditions. Brain 1897; 20:138-179.
6. Tanaka H, Yoshida M, Ishiguro T, Eguchi C, Nonaka I, Ozawa E. Expression of dystrophin on the cell membrane of intrafusal fibers of human skeletal muscle. Protoplasma 1989; 152:109-111.
7. Noakes TD. Effect of exercise on serum enzyme activities in humans. Sports Med 1987; 4:245-267.
8. Florence JM, Fox PT, Planer GJ, Brooke MH. Activity, creatine kinase, and myoglobin in Duchenne muscular dystrophy: a clue to etiology? Neurology 1985; 35:758-761.
9. Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem (Tokyo) 1995; 118:959-964.
10. Lidov H, Byers TJ, Watkins SC, Kunkel LM. Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons. Nature 1990; 348:725-728.
11. Hagiwara Y, Yoshida M, Nonaka I, Ozawa E. Developmental expression of dystrophin on the plasma membrane of rat muscle cells. Protoplasma 1989; 151:11-18.
12. Monaco AP, Kunkel LM. Cloning of the Duchenne/Becker muscular dystrophy locus. Adv Hum Genet 1988; 17:61-98.
13. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988; 53:219-228.
14. Tinsley JM, Blake DJ, Zuelling RA, Davies KE. Increasing complexity of the dystrophin-associated protein complex. Proc Natl Acad Sci USA 1994; 91:8307-8313.
15. Blake DJ, Weir A, Sarah E Newey, Kay E Davies. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002; 82:291-329.
16. Ozawa E. The muscle fiber cytoskeleton: The dystrophin system. In: Engel A, Franzini-Armstrong C, eds. Myology. New York: McGraw-Hill, 2004:455-470.
17. Yoshida M, Suzuki A, Yamamoto, H, Noguchi S, Ozawa E. Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n-octyl b-D-glucoside. Eur J Biochem 1994; 222:1055-1061.
18. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992; 355:696-702.
19. Chiba A, Matsumura K, Yamada H, et al. Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin. J Biol Chem 1997; 272:2156-2162.
20. Ozawa E, Noguchi S, Mizuno Y, Hagiwara Y, Yoshida M. From dystrophi-nopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy. Muscle Nerve 1998; 21:421-438.
21. Ozawa E, Mizuno Y, Hagiwara Y, Sasaoka T, Yoshida M. Molecular and cell biology of sarcoglycan complex. Muscle Nerve 2005; 32:563-576.
22. Crosbie RH, Heighway J, Venzke DP, Lee JC, Campbell KP. Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex. J Biol Chem 1997; 272:31221-1224.
23. Winder SJ, Gibson TJ, Kendrick-Jones J. Dystrophin and utrophin: the missing links!. FEBS Lett 1995; 369:27-33.
24. Sutherland-Smith AJ, Moores CA, Norwood FL, et al. An atomic model for actin binding by the CH domains and spectrin-repeat modules of utrophin and dystrophin. J Mol Biol 2003; 329:15-33.
25. Rybakova I, Amann KJ, Ervasti JM. A new model for the interaction of dystrophin with F-actin. J Cell Biol 1996; 135:661-671.
26. Ishikawa-Sakurai M, Yoshida M, Imamura M, Davies K, Ozawa E. ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to b-dystroglycan. Hum Mol Genet 2004; 13:693-702.
27. Ozawa E, Nishino I, Nonaka I. Sarcolemmopathy: muscular dystrophies with cell membrane defects. Brain Pathol 2001; 11:218-230.
28. Yoshida M, Hama H, Ishikawa-Sakurai M, et al. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet 2000; 9:1033-1040.
29. Noguchi S, Wakabayashi E, Imamura M, Yoshida M, Ozawa E. Formation of sarcoglycan complex with differentiation in cultured myocytes. Eur J Biochem 2000; 267:640-648.
30. Wakayama Y, Shibuya S. Gold-labelled dystrophin molecule in muscle plas-malemma of mdx control mice as seen by electron microscopy of deep etching replica. Acta Neuropathol 1991; 82:178-184.
31. Andre B, Springer J-Y. WWWP, a new amino acid motif present in single or multiple copies in various proteins including dystrophin and SH3-binding Yes-associated protein YAP65. Biochem. Biophys Res Comm 1994; 205:1201-1205.
32. Bork P, Sudol M. The WW domain: a signaling site in dystrophin? TIBS 1994; 19:531-533.
33. Zarrinpar A, Lim WA. Converging on proline: the mechanism of WW domain peptide recognition. Nat Struct Biol 2000; 7:611-613.
34. Huang X, Poy F, Zhang R, Joakimiak A, Sudol M, Eck MJ. Structure of a WW domain containing fragment of dystrophin in complex with b-dystrogly-can. Nat Struct Biol 2000; 7:634-638.
35. Rafael JA, Cox GA, Corrado K, Jung D, Campbell KP, Chamberlain JS. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 1996; 134:93-102.
36. Talts JF, Andac Z, Gohring W, Brancaccio A, Timpl R. Binding of the G domains of laminin a1 and a2 chains and perlecan to heparin, sulfatides, a-dystroglycan and several extracellular matrix proteins. EMBO J 1999; 18:863-870.
37. Sakamoto A, Ono K, Abe M, et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, 8-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997; 94:13873-13878.
38. Noguchi S, Wakabayashi E, Imamura, Yoshida M, Ozawa E. Developmental expression of sarcoglycan gene products in cultured myocytes. Biochem Bio-phys Res Commun 1990; 262:88-93.
39. Imamura M, Mochizuki Y, Engvall E, Takeda S. e-Sarcoglycan compensate for lack of a-sarcoglycan in a mouse model of limb-girdle muscular dystrophy. Hum Mol Genet 2005; 14:775-783.
40. Burkin DJ, Kaufman SJ. The a7p1 integrin in muscle developmemt and disease. Cell Tissue Res 1999; 296:183-190.
41. Kerr TP, Sewry CA, Robb SA, Roberts RG. Long mutant dystrophins and variable phenotypes: evasion of nonsense mediated decay? Human Genet 2001; 109:402-407.
42. Chelly J, Kaplan JC, Maire P, Gautron S, Kahn A. Transcription of the dystrophin gene in human muscle and non-muscle tissue. Nature 1988; 333:858-860.
43. Tanaka H, Ishiguro T, Eguchi C, Saito K, Ozawa E. Expression of a dystrophin-related protein associated with the skeletal muscle cell membrane. Histochemistry 1991; 96:1-5.
44. Squire S, Raymackers JM, Vandebrouck C, et al. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet 2002; 11:3333-3344.
45. Deckonick AE, Rafael JA, Skinner JA, et al. Utrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997; 90:717-727.
46. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 1997; 90:729-738.
47. Rafael JA, Tinsley, Potter AC, Deconinck AE, Davies KE. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet 1998; 19:79-83.
48. Mizuno Y, Yoshida M, Nonaka I, Hirai S, Ozawa E. Expression of utrophin (dystrophin-related protein) and dystrophin-associated glycoproteins in muscles from patients with Duchenne muscular dystrophy. Muscle Nerve 1994; 17:206-216.
49. Ohlendieck K, Matsumura K, Ioanescu VV, et al. Duchenne muscular dystrophy: Deficiency of dystrophin associated proteins in the sarcolemma. Neurology 1993; 43:795-800.
50. Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995; 82:743-752.
51. Metzinger L, Blake DJ, Squier MV, et al. Dystrobrevin deficiency at the sarcolemma of patients with muscular dystrophy. Hum Mol Genet 1997:1185-1191.
52. Kameya S, Miyagoe Y, Nonaka I, et al. a1-Syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J Biol Chem 1999; 274:2193-2200.
53. Chao DS, Silvagno F, Bredt DS. Muscular dystrophy in mdx mice despite lack of neuronal nitric oxide synthase. J Neurochem 1998; 71:784-789.
54. Grady RM, Grange RW, Lau KS, et al. Role for a-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1999; 1:215-220.
55. Cox GA, Cole NM, Matsumura K, et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 1993; 364:725-729.
56. Noguchi S, Tsukahara T, Fujita M, et al. cDNA microarray analysis of individual Duchenne muscular dystrophy patients. Hum Mol Genet 2003; 12: 595-600.
57. Winnard AV, Klein CJ, Coovert DD, et al. Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. Hum Mol Genet 1993; 2:737-744.
58. Hoffman EP, Fischbeck KH, Brown RH, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy. N Engl J Med 1988; 26 (318):1363-1368.
59. Warner LE, DelloRusso C, Crawford RW, et al. Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Hum Mol Genet 2002; 11:1095-1105.
60. Cox GA, Sunada Y, Campbell KP, Chamberlain JS. Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat Genet 1994; 8:333-339.
61. Greenberg DS, Sunada Y, Campbell KP, Yaffe D, Nudel U. Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice. Nat Genet 1994; 8:340-344.
62. Hoffman EP, Garcia CA, Chamberlain JS, Angelini C, Lupski JR, Fenwick R. Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of Duchenne muscular dystrophy. Ann Neurol 1991; 30:605-610.
63. Recan D, Chafey P, Leturcq F, et al. Are cysteine-rich and COOH-terminal domains of dystrophin critical for sarcolemmal localization? J Clin Invest 1992; 89:712-716.
64. Helliwell TR, Ellis JM, Mountford RC, Appleton RE, Morris GE. A truncated dystrophin lacking the C-terminal domains is localized at the muscle membrane. Am J Hum Genet. 1992; 50:508-514.
65. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989; 45:498-506.
66. Den Dunnen JT, Grootscholten PM, Bakker E, et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 1989; 45:835-847.
67. Hodgson S, Hart K, Abbs S, et al. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy. J Med Genet 1989; 26:682-693.
68. Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehner SC, Chamberlain JS. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol 2000; 150:1399-1410.
69. England SB, Nicholson LV, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990; 343:180-182.
70. Dunckley MG, Love DR, Davies KE, Walsh FS, Morris GE, Dickson G. Ret-roviral-mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro. FEBS Lett 1992; 296:128-134.
71. Ozawa E, Yoshida M, Suzuki A, Mizuno Y, Hagiwara Y, Noguchi S. Dystrophin-associated proteins in muscular dystrophy. Hum Mol Genet 1995; 4:1711-1716.
72. Yuasa K, Miyagoe Y, Yamamoto K, Nabeshima Y, Dickson G, Takeda S. Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett 1998; 425:329-336.
73. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10:828-834.
74. Sakamoto M, Yuasa K, Yoshimura M, et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 2002; 293:1265-1272.
75. Tome FM, Evangelista T, Leclerc A, et al. Congenital muscular dystrophy with merosin deficiency. CR Acad Sci III 1994; 317:351-357.
76. Yoshida A, Kobayashi K, Manya H, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001; 1:717-724.
77. Muntoni F, Voit T. The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul Disord 2004 ; 14:635-649.
78. Voit T, Tome FMS. The congenital muscular dystrophies. In: Engel A, Fran-zini-Armstrong C , eds. Myology. New York: McGraw-Hill, 2004:1203-1238.
79. Hayashi YK, Chou FL, Engvall E, et al. Mutations in the integrin alpha7 gene cause congenital myopathy. Nat Genet 1998; 19:94-97.
80. Osari S, Kobayashi O, Yamashita Y, et al. Basement membrane abnormality in merosin-negative congenital muscular dystrophy. Acta Neuropathol (Berl) 1996; 91:332-336.
81. Tomanek RJ, Colling-Saltin AS. Cytological differentiation of human fetal skeletal muscle. Am J Anat 1977; 149:227-245.
82. Chiu AY, Sanes JR. Development of basal lamina in synaptic and extrasynap-tic portions of embryonic rat muscle. Dev Biol 1984; 103:456-467.
83. Clerk A, Strong PN, Sewry CA. Characterization of dystrophin during development of human skeletal muscle. Development 1992; 114:395-402.
84. Clerk A, Sewry CA, Dubowitz V, Strong PN. Characterization of dystrophin in fetuses at risk for Duchenne muscular dystrophy. J Neurol Sci 1992; 111:82-91.
85. Clerk A, Morris GE, Dubowitz V, Davies KE, Sewry CA. Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. His-tochem J 1993; 25:554-561.
86. Tome FM, Matsumura K, Chevallay M, Campbell KP, Fardeau M. Expression of dystrophin-associated glycoproteins during human fetal muscle development: a preliminary immunocytochemical study. Neuromuscul Disord 1994; 4:343-348.
87. Carpenter S, Karpati G. Duchenne muscular dystrophy: plasma membrane loss initiates muscle cell necrosis unless it is repaired. Brain 1979; 102:147-161.
88. Henry MD, Campbell KP. A role for dystroglycan in basement membrane assembly. Cell 1998; 95:859-870.
89. Lazarides E. Intermediate filaments as mechanical integrators of cellular space. Nature 1980; 283:249-256.
90. Pardo JV, Siliciano JD, Craig SW. A vinculin-containing cortical lattice in skeletal muscle: transverse lattice elements (‘‘costameres’’) mark sites of attachment between myofibrils and sarcolemma. Proc Natl Acad Sci USA 1983; 80:1008-1012.
91. Danowski BA, Imanaka-Yoshida K, Sanger JM, Sanger JW. Costameres are sites of force transmission to the substratum in adult rat cardiomyocytes. J Cell Biol 1992; 118:1411-1420.
92. Hijikata T, Fujimaki N, Osawa H, Ishikawa H. The direct visualization of structural array from laminin to dystrophin in sarcolemmal vesicles prepared from rat skeletal muscles. Biol Cell 1998; 90:629-639.
93. Mizuno Y, Thompson TG, Guyon JR, et al. Desmuslin, an intermediate filament protein that interact with a-dystrobrevin and desmin. Proc Natl Acad Sci USA 2001; 98:6156-6161.
94. Hijikata T, Murakami T, Ishikawa H, Yorifuji H. Plectin tethers desmin intermediate filaments onto subsarcolemmal dense plaques containing dystrophin and vinculin. Histochem Cell Biol 2003; 119:109-123.
95. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2001; 82: 291-329.
96. Pardo JV, Siliciano JD, Craig SW. Vinculin is a component of an extensive network of myofibril-sarcolemma attachment regions in cardiac muscle fibers. J Cell Biol 1983; 97:1081-1088.
97. Dowben RM. Contractility. In: Mountcastle VB, ed. Medical Physiology. St Louis: C.V. Mosby Company, 1980:82-119.
98. Masuda T, Fujimaki N, Ozawa E, Ishikawa H. Confocal laser microscopy of dystrophin localization in guinea pig skeletal muscle fibers. J Cell Biol 1992; 119:543-548.
99. McNeil PL, Terasaki M. Coping with the inevitable: how cells repair a torn surface membrane. Nat Cell Biol 2001; 3:E124-129.
100. Ozawa E, Hagiwara Y, Yoshida M. Creatine kinase, cell membrane and Duchenne muscular dystrophy. Mol Cell Biochem 1999; 190:143-151.
101. Smith FJS, Eady RA, Leigh IM, et al. Plectin deficiency results in muscular dystrophy with epidermolysis bullosa. Nat Genet 1996; 13:450-457.
102. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000; 342:770-780.
103. Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000; 9:2141-2147.
104. Moreira ES, Wiltshire TJ, Faulkner G, et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet 2000; 24:163-116.
105. Sorimachi H, Ishiura S, Suzuki K. Structure and physiological function of cal-pains. Biochem J 1997; 328:721-732.
106. Ozawa E, Hosoi S, Ebashi S. Reversible stimulation of muscle phospho-rylase b kinase by low concentration of Ca ions. J Biochem (Tokyo) 1967; 61:531-533.
107. Ozawa E. Activation of muscular phosphprylase b kinase by a minute amount of Ca ion. J Biochem (Tokyo) 1972; 71:321-331.
108. Koch R. Die Aetiologie der Tuberklose. Addressed at the Berlin Physiological Society 1882. In: Porter R (Summarized). In: The Greatest Benefit to Mankind. New York: W W Norton Co, 1997:436-437.
109. Ebashi S, Endo M. Calcium ion and muscle contraction. Prog Biophys Mol Biol. 1968; 18:123-183.
110. Sorimachi H, Imajoh-Ohmi S, Emori Y, et al. Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem 1989; 264:20106-20111.
111. Ishiura S, Tsuji S, Murofushi H, Suzuki K. Purification of an endogenous 68,000-dalton inhibitor of Ca2+-activated neutral protease from chicken skeletal muscle. Biochim Biophys Acta 1982; 701:216-223.
112. Isselbacher KJ, et al., eds. Harrison’s Principles of Internal Medicine. 13th edn. New York: McGraw Hill, Inc., 1994:2490.
113. Iwata Y, Katanosaka Y, Arai Y, Komamura K, Miyatake K, Shigekawa M. A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel. J Cell Biol 2003; 161:957-967.
114. Endo M, Yagi S, Ishizuka T, Horiuti K, Koga Y, Amaha K. Changes in the Ca-induced Ca release mechanism in the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia. Biomed Res 1983; 4:83-92.
115. Cullen MJ, Fulthorpe JJ. Stages in fibre breakdown in Duchenne muscular dystrophy. An electron-microscopic study. J Neurol Sci 1975; 24:179-200.
116. Suzuki K, Saido TC, Hirai S. Modulation of cellular signals by calpain. Ann NY Acad Sci. 1992; 674:218-227.
117. Croall DE, DeMartino GN. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol Rev 1991; 71:813-847.
118. Suzuki A, Yoshida M, Yamamoto H, Ozawa E. Glycoprotein-binding site of dystrophin is confined to the cysteine-rich domain and the first half of the car-boxy-terminal domain. FEBS Lett 1992; 308:154-160.
119. Spencer MJ, Mellgren RL. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum Mol Genet 2002; 11:2645-2655.
120. Porter JD, Khanna S, Kaminski HJ, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophic-deficient mdx mice. Human Mol Genet 2002; 11:263-272.
121. Zak R, Martin AF, Blough R. Assessment of protein turnover by use of radioisotopic tracers. Physiol Rev 1979; 59:407-447.